fascaplysine has been researched along with Metastase in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Guan, X; Li, B; Liu, Y; Sang, XB; Wang, LL; Zhao, Y | 1 |
| Collins, DM; Crown, J; Eustace, AJ; Mahgoub, T; O'Donovan, N; Walsh, N | 1 |
2 other study(ies) available for fascaplysine and Metastase
| Article | Year |
|---|---|
Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Vascular Endothelial Growth Factor A | 2017 |
Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Melanoma; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Sulfonamides; Vemurafenib | 2015 |